Tag Archives: business

Hot Investor Mandate: Seed Stage Investor Focuses on Pre-Clinical Drug Discovery Companies in CNS, Oncology, and Other Indications, Supporting Them for Clinical Readiness

3 Sep

A venture capital investor primarily makes angel investments in seed-stage companies and works hands-on with portfolio companies to facilitate regulatory approval and commercialization. Typical initial check size is in the $500–750K range, with tranche investments possible beyond this amount. The firm is open to global opportunities. 

The firm focuses on therapeutics companies in the early stages of drug discovery and development. Current areas of interest include CNS and neurodegenerative diseases, oncology, and pulmonary diseases pursued with novel approaches. While the firm works primarily with pre-clinical opportunities, it may consider other indications from time to time. 

The firm’s long-term strategy is to help companies progress toward Phase II readiness for pre-clinical assets. With broad expertise in regulatory and toxicology matters, the firm takes a hands-on approach to supporting portfolio companies. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Experience the Innovation at RESI Boston 2025! 

3 Sep

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

The Innovator’s Pitch Challenge (IPC) is a highlight of RESI Boston, bringing early-stage life science startups into the spotlight. Finalists will present across multiple sessions, showcasing breakthroughs in therapeutics, medical devices, diagnostics, digital health solutions, and R&D tools. Each pitch is delivered to a panel of active investors and industry experts who provide interactive questions and constructive feedback, while attendees also get a front-row seat to see the next wave of healthcare innovation.

RESI attendees are more than just spectators; they play an active role in the competition by “investing” their RESI cash in the companies they believe in most. This unique format allows the community to engage directly with the innovators, and the winners are revealed after the votes are tallied during the closing cocktail reception.

IPC participants also benefit from one-on-one partnering, exhibit space in the RESI Exhibition Hall, and the chance to compete for complimentary registration at future RESI conferences. Here are the presenting companies at RESI Boston September:

While applications to the IPC are now closed, you can still register for RESI Boston September 2025 to take part in everything the conference has to offer — from casting your vote in the IPC, to connecting with investors, attending panels and workshops, and making valuable new partnerships.

Tags: , , , , , ,

FREE Pre-RESI Event: Structuring Your Startup: Legal, Tax, Funding, and Strategic Decisions

3 Sep

By Max Braht, Director of Business Development, LSN

Max-Braht-Headshot

Life Science Nation (LSN) invites early-stage life science and healthcare companies to a free, in-person pre-conference event designed to equip founders and executives with the knowledge and tools to build a successful venture in the U.S. market.

Structuring Your Startup: Legal, Tax, Funding, and Other Strategic Decisions will be held on Tuesday, September 16, from 1:00–5:00 PM at CIC Cambridge, Havana Room, One Broadway, Cambridge, MA. Taking place the day before RESI Boston 2025 (September 17–19), this workshop is a valuable opportunity for companies in town for Biotech Week Boston to gain practical insights and make new connections.

Attendees will hear from leading organizations, including Polsinelli, Eva Garland, LabCentral, Savills, and EisnerAmper, along with LSN, on the critical decisions that shape an emerging life science company. Topics will span legal frameworks, risk mitigation, tax considerations, fundraising approaches, deal structuring, operational planning, and pathways for life science companies entering or looking to scale within the U.S. market.

The program also features time dedicated to networking, giving founders and executives the chance to connect with peers, advisors, and potential partners before the RESI conference begins.

This pre-conference session is part of LSN’s ongoing effort to support life science entrepreneurs in landing their companies in the Boston innovation ecosystem and expanding into the U.S. market.

Registration is free, but space is limited. Don’t miss your chance to join.

Tags: , , , , , , , , , , , ,

Corporate VC Panel: Venture and Innovation Arms Making Strategic Investments

3 Sep

By Joey Wong, Director of Investor Research, Hong Kong BD, LSN

Joey-New-Headshot

Many large corporations establish ventures or innovation arms to invest in and partner with life science and healthcare startups. Unlike traditional institutional VCs, corporate venture capital (CVC) groups bring unique strategies, goals, and ties to their parent organizations. Some CVCs focus closely on opportunities that align with the corporation’s core businesses, while others pursue innovation beyond existing portfolios, creating broader avenues for collaboration.

This 50-minute discussion will bring together leaders from corporate venture arms of global pharma, biotech, medtech, and healthcare corporations. Panelists will share how they evaluate early-stage opportunities, what distinguishes their investment criteria from institutional VCs, and how they balance strategic alignment with financial return. Startups will also gain valuable perspective on how to approach CVCs, what additional benefits they can expect beyond funding, and how relationships and collaboration may evolve post-investment.

For entrepreneurs seeking strategic partners, this session offers a chance to hear directly from active CVC investors about how they drive innovation, accelerate R&D, and bring transformative solutions to the market.

Andrew-Merken
Andrew Merken
Shareholder
Polsinelli PC
(Moderator) 		Komeil-Nasrollahi
Komeil Nasrollahi
Sr. Director Innovation & Venture Partnerships
Siemens Healthineers 		Claire-Leurent
Claire Leurent
Managing Director
AbbVie Ventures
Jeffrey-Moore
Jeffrey Moore
President
MP Healthcare Venture Management (MPH) 		Alex-de-Winter
Alex de Winter
VP of New Ventures
Danaher Corporation

Join us at RESI Boston this September to take part in this discussion and connect with investors across the life science and healthcare ecosystem.

Tags: , , , , ,

Hot Investor Mandate: Corporate Venture Arm of Global Manufacturing Company Makes Strategic Investments in Medical Devices, Diagnostics, and Biomanufacturing

26 Aug

A global manufacturing company operates across a wide range of industries, including analytical, medical, and industrial equipment. In recent years, the firm has placed a strong focus on healthcare, particularly in clinical diagnostics and biomanufacturing. 

A few years ago, the firm established a corporate venture capital (CVC) division to seek strategic partnerships with companies that possess cutting-edge technologies aligned with its business areas.  

The firm has invested in companies across the U.S., Canada, and Asia and is actively looking to expand its portfolio. While the CVC primarily targets investments in Seed to Series A rounds, it may also consider Series B opportunities. Typical check sizes range from $1 million to $5 million USD, though larger investments are possible for particularly promising technologies. 

Within healthcare, the firm is seeking opportunities in clinical diagnostics, medical devices, and biomanufacturing. The firm is open to not only hardware but also consumables and software solutions. 

To attract investment from the CVC, having a lead investor is desirable. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: USA-Based VC Firm Seeks Novel Therapeutics and Platform Technologies, Investing Up to $30M Over Company Lifecycle

26 Aug

A venture capital firm based in the US is actively investing in life science companies. The firm primarily invests in therapeutics companies in early and growth stage. Typical check sizes are in the $25-30M range over the company’s life cycle. The firm has a preference for companies based in Los Angeles and is passionate about fostering the local life science ecosystem, but the firm is also open to investing outside of LA given that the opportunity is a great fit. Outside of LA, the firm invests almost exclusively in the US. 
 
The firm invests in therapeutics in all disease areas and modalities, and is open to both single assets and platform technologies. The firm currently has over 20 companies in their portfolio, which can be reviewed here: https://westlakebio.com/portfolio for a better sense of where the firm has invested to date.  

The firm is open to pre-clinical to early clinical stage opportunities. The firm is open to investing in promising companies even in the idea/conception stage, and has done so in the past. 
 
The firm looks for compelling technologies and is open to investing in companies founded by first-time entrepreneurs. The firm prefers to be a lead investor, and has always led Series A investments and seeks board representation when leading. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: Venture and Growth Investment Firm Seeks Early-Stage Life Sciences Companies in the US, Open to All Sectors

26 Aug

A growth and venture investor based in the U.S. typically engages in pre-clinical and Seed stage life science startups. The firm invests in companies focused on significant unmet medical needs across contract services, manufacturing, equipment, and therapeutic companies. The firm supports entrepreneurs and early-stage companies by providing deep expertise, industry knowledge, and a network of proven experts to guide them through every stage of their life cycle. 

The firm is interested in pre-clinical therapeutics, digital health, medical devices, and diagnostic companies. The firm also invests in contract services, enabling technologies, and therapeutics across cell and gene therapies, oncology, antimicrobial resistance, neurosciences, and rare diseases. While indication-agnostic, the firm has particular expertise in oncology, neurosciences, rare disease, and antimicrobial resistance. 

The firm does not have strict company or management team requirements. The firm may take a board seat on a case-by-case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

← Older Entries
Newer Entries →